Sanofi SA vs Vale SA — how do they compare? Sanofi SA trades at $43.52 (market cap $104.57B), while Vale SA trades at $14.39 (market cap $62.26B). The key difference: Sanofi SA is the larger of the two by market cap, and Vale SA pays the higher dividend (8.12%). Which is the better fit depends on your goals.
| SNY | VALE | |
|---|---|---|
Market Cap | $104.57B | $62.26B |
Sector | Health | Basic Materials |
52-Week High | $52.34 | $17.82 |
52-Week Low | $41.33 | $9.71 |
Enterprise Value | $124.48B | $78.50B |
Dividend Yield | 5.56% | 8.12% |
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →